American Journal of Kidney Diseases

Additive antiproteinuric effect of converting enzyme inhibitor and losartan in normotensive patients with IgA nephropathy


      We tested the hypothesis that the combination of converting enzyme inhibitor (CEI) with losartan (LOS) produces a more profound antiproteinuric effect than either drug alone in normotensive patients with immunoglobulin A (IgA) nephropathy. Eight normotensive (mean blood pressure, 88.9 ± 2.1 mm Hg) patients with biopsy-proven IgA nephropathy, nonnephrotic proteinuria (protein, 1 to 3 g/d), and normal or slightly reduced creatinine clearance (range, 69 to 119 mL/min) were studied. Clinical evaluations and laboratory tests were performed (1) before CEI treatment (basal) and after (2) CEI alone (CEI, 12 weeks); (3) the combination of CEI and LOS, the latter at a dosage of 50 mg/d (CEI + LOS, 4 weeks); (4) LOS alone (LOS; 50 mg/d; 12 weeks); (5) the combination of LOS and CEI (LOS + CEI, 4 weeks, at the same dosage as CEI + LOS); and (6) a doubled dose of either CEI alone or LOS alone for 4 weeks. CEI and LOS as monotherapy significantly reduced proteinuria by 38% and 30%, respectively. No further reduction of proteinuria was achieved by doubling the dose of CEI or LOS. Both combinations induced a more remarkable reduction of proteinuria (73%; P < 0.05 v other periods) than either drug administered alone. The antiproteinuric effect of CEI or LOS and the more remarkable effect achieved with both combinations was not dependent on the reduction of blood pressure and/or creatinine clearance. In conclusion, this study provides first-time evidence that the combination of CEI and LOS in normotensive patients with IgA nephropathy produces a more profound decrease in proteinuria than either drug. This additive antiproteinuric effect is not dependent on changes in systemic blood pressure and creatinine clearance. Nevertheless, a larger controlled study is required to confirm this novel observation.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to American Journal of Kidney Diseases
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Maschio G
        • Alberti D
        • Janin G
        • Locatelli F
        • Mann JFE
        • Motolese M
        • Ponticelli C
        • Ritz E
        • Zucchelli P
        Effect of the angiotensin-converting enzyme inhibitor benazepril on the progression of chronic renal insufficiency.
        N Engl J Med. 1996; 334: 939-945
        • Cattran DC
        • Greenwood C
        • Ritchie S
        Long-term benefits of angiotensin-converting enzyme inhibitor therapy in patients with severe immunoglobulin A nephropathy: A comparison to patients receiving treatment with other antihypertensive agents and to patients receiving no therapy.
        Am J Kidney Dis. 1994; 23: 247-254
        • Ravid M
        • Lang R
        • Rachmani R
        • Lishner M
        Long-term renoprotective effect of angiotensin-converting enzyme inhibition in non–insulin-dependent diabetes mellitus.
        Arch Intern Med. 1996; 156: 286-289
        • Peterson JC
        • Adler S
        • Burkart JM
        • Greene T
        • Hebert LA
        • Hunsicker L
        • King A
        • Khlar S
        • Massry SG
        • Seifter JL
        Blood pressure control, proteinuria and the progression of renal disease.
        Ann Intern Med. 1995; 123: 754-762
        • Matsusaka T
        • Hymes J
        • Ichikawa I
        Angiotensin in progressive renal diseases. Theory and practice.
        J Am Soc Nephrol. 1996; 7: 2025-2043
        • Mento PF
        • Wilkes BM
        Plasma angiotensins and blood pressure during converting enzyme inhibition.
        Hypertension. 1987; 9: S42-S48
        • Biollatz J
        • Brunner HR
        • Gavras I
        • Weaber B
        • Gavras H
        Antihypertensive therapy with MK-421: Angiotensin II–renin relationship to evaluate efficacy of converting enzyme inhibition.
        J Cardiovasc Pharmacol. 1982; 4: 966-972
        • Urata H
        • Bohem KD
        • Philip A
        • Kinoshita A
        • Gabrovsek J
        • Bumpus M
        • Husain A
        Cellular localization and regional distribution of an angiotensin II–forming chymase in the heart.
        J Clin Invest. 1993; 91: 1269-1281
        • Remuzzi A
        • Perticucci E
        • Ruggenenti P
        • Mosconi L
        • Limonta M
        • Remuzzi G
        Angiotensin-converting enzyme inhibition improves glomerular size-selectivity in IgA nephropathy.
        Kidney Int. 1991; 39: 1267-1273
        • Russo D
        • Minutolo R
        • Cianciaruso B
        • Memoli B
        • Conte G
        • De Nicola L
        Early effects of contrast media on renal hemodynamics and tubular function in chronic renal failure.
        J Am Soc Nephrol. 1995; 6: 1451-1458
        • The GISEN Group
        Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy.
        Lancet. 1997; 349: 1857-1863
        • Heeg JE
        • de Jong PE
        • Van Der Hem GK
        • de Zeeuw D
        Reduction of proteinuria by angiotensin-converting enzyme inhibition.
        Kidney Int. 1987; 32: 78-83
        • Azizi M
        • Guyene TT
        • Chatellier G
        • Wargon M
        • Ménard J
        Additive effects of losartan and enalapril on blood pressure and plasma active renin.
        Hypertension. 1997; 29: 634-640
        • Burnier M
        • Rutschumann B
        • Nussberger J
        • Versaggi J
        • Shainfar S
        • Waeber B
        • Brunner HR
        Salt-dependent renal effects of an angiotensin II antagonist in healthy subjects.
        Hypertension. 1993; 22: 339-347
        • Burnier M
        • Hagman M
        • Nussberger J
        • Biollaz J
        • Armagnac C
        • Brouard R
        • Waeber B
        • Brunner HR
        Short-term and sustained renal effects of angiotensin II receptor blockade in healthy subjects.
        Hypertension. 1995; 25: 602-609
        • Goldberg MR
        • Tanaka W
        • Berchowsky A
        • Bradstreet TE
        • McCrea J
        • Lo MW
        • McWilliams EJ
        • Djornsson TD
        Effects of losartan on blood pressure, plasma renin activity, and angiotensin II in volunteers.
        Hypertension. 1993; 21: 704-713
        • Gansevoort RT
        • De Zeeuw D
        • De Jong PE
        Is the anti-proteinuric effect of ACE inhibition mediated by interference in the renin-angiotensin system?.
        Kidney Int. 1994; 45: 861-867